Understanding Change at Scale
The time and expense of conducting clinical studies are often the biggest barriers to the commercialization of promising genomic tests. DxTerity’s Direct-to-Patient Clinical Research Platform addresses this problem by enabling population-scale genomic studies to be conducted within the controlled environment of a regulatory compliant clinical trial.
Study Planning and Support
DxTerity enables partners to conduct cost-effective and compliant "from home" studies. DxTerity conducts its study planning with centralized Institutional Review Board oversight, or in concert with traditional academic research centers and partner contract research providers. DxTerity has conducted studies ranging from observational trials for Real World Evidence to Phase III and IV trials with clinical endpoints.
DxTerity uses digital recruiting methods that reach participants nationwide. By engaging patients at home, DxTerity provides the access and convenience that is needed for effective real world evidence studies. The DxCollect® kits can be mailed directly to consented study participants and returned by US mail. No visits to blood collection centers are required, thereby increasing access to and compliance of participants in remote areas.
Real World Evidence for Understanding Complex Disease
Patients with autoimmune disease are often on multiple drug therapies. Understanding the impact of various drugs on different patient populations requires the ability to characterize complex combinations of therapies and conditions, and to separate pathway and disease activities unique to sub-populations. DxTerity’s technology and approach to large population-scale genomic studies provides comprehensive insights into these types of research challenges.